omniture
logo
Search
信达生物制药（苏州）有限公司 Innovent BiologicsInc
Media Room

Latest News

rss

Innovent Releases Preliminary Results of the Phase Ia Dose-Escalation study of IBI315 (Anti-Her2/PD-1 Bispecific Antibody) in Patients with Advanced Solid Tumors at CSCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, Sept. 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-09-29 08:00 4431

Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions

SAN FRANCISCO and SUZHOU, China and HELLERUP, Denmark, Sept. 28, 2021 /PRNewswire/ -- Innovent Biol...

2021-09-28 08:00 4691

Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2021-09-27 08:00 4617

Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis

SAN FRANCISCO and SUZHOU, China, Sept. 24, 2021 /PRNewswire/ -- Innovent Biologics, Group. ("Innove...

2021-09-24 08:00 4390

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC)

SAN FRANCISCO and SUZHOU, China, Sept. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2021-09-23 08:00 4650

Innovent Releases Interim Analysis Results of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in the Phase 3 ORIENT-16 Study at ESMO Congress 2021

SAN FRANCISCO and SUZHOU, China, Sept. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-09-18 08:00 16067

Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021

SAN FRANCISCO and SUZHOU, China, Sept. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-09-18 08:00 8227

Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021

SAN FRANCISCO and SUZHOU, China, Sept. 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-09-17 08:00 7073

Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-09-08 08:00 8421

Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)

SAN FRANCISCO and SUZHOU, China, Sept. 2, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-09-02 08:00 6431

Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021

SAN FRANCISCO and SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-08-30 08:00 4587
1 ... 1011121314